Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patient
Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate.
Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of
Ipsen’s big partnering push to expand its pipeline shows no signs of abating, with the latest deal a $1 billion wager on an antibody-drug conjugate (ADC) for cancer developed by Foreseen Bi
There is change at the top of AbbVie’s R&D organisation, as chief scientific officer Thomas Hudson announces his retirement after four years in the role.
